Ovarian cancer is one of the most common types of cancer in women. While funding for research into this area has declined in the UK, the depth of research continues to lag behind other cancer types.
In most areas of medicine, it is difficult to carry out sustained, high quality research without the support of external funding. Many students are met with the difficulty, that in order to submit a credible application for funding with a reasonable chance of success, they are expected to have undertaken preliminary research prior to this. Many struggle to get to this stage due to a lack of funding, leaving fantastic research proposals undetected and unnoticed. With this in mind, Swansea University aims to award seed-corn research grants to talented medical students who aim to undertake extraordinary and ground breaking research, bridging the gap between the ordinary and the extraordinary.
The Medical Research Fund aims to enable young researchers to use their disciplinary expertise in multidisciplinary contexts, supporting work that crosses traditional boundaries and potentially saves lives. The Medical School at Swansea University is ranked 1st in the UK for research environment and with your support we can help translate the highest quality research into extraordinary advances whilst maintaining our high standard for research quality.
Providing a platform for young researchers
Ovarian cancer is one of the most common types of cancer in women, has the highest mortality rate of all female reproductive system cancers worldwide, and is frequently diagnosed at a late stage of the disease. Patients initially respond well to chemotherapy, but even after successful treatment there is a high chance the cancer will come back within the next few years. If it does come back, it can’t usually be cured with a five-year survival rate of only 27%.
Through funding from The Medical Research Fund, early-cancer researchers at Swansea University, Dr James Cronin and Dr Martin Clift have been given the stepping stone needed to investigate whether targeting therapy-resistant ovarian cancer cells with nanoparticles induces cancer cell death. This study will generate preliminary data that will contribute to the submission of a larger study grant with the ultimate aim of producing novel therapeutics to target chemotherapy resistance in ovarian cancer.
To find out how you can support your University by making a donation, please contact Catrin Harris via email, or phone on 01792 604626
- Tuesday 26 June 2018 15.40 BST
- Tuesday 26 June 2018 14.44 BST
- Ffion White